<DOC>
	<DOCNO>NCT01667341</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled , dose escalation study . There 3 cohort patient define antigen dose ( 10 , 30 100 µg antigen ) , within cohort , patient randomize ratio 3:1:1 one following : 1 . GEN-003/M2 : GEN-003 plus Matrix M-2 adjuvant ( 50 µg per dose ) 2 . GEN-003 : Antigens alone 3 . Placebo ( DPBS diluent ) Each Cohort divide 2 Groups . For dose cohort , immunization begin Pilot Group . Immunization remainder Group `` Continuation Group '' ) contingent upon successful review data Pilot Group Day 7 immunization . Dose escalation next dose level Cohort proceed evaluation safety data patient prior Cohort specify safety criterion meet . The total number patient Group Cohort follow : - 10 µg Cohort : 10 Pilot Group , 40 Continuation Group ( 50 Total ) - 30 µg Cohort : 10 Pilot Group , 40 Continuation Group ( 50 Total ) - 100 µg Cohort : 10 Pilot Group , 40 Continuation Group ( 50 Total ) - Totals per group : 30 Pilot Group , 120 Continuation Group ( 150 Total Patients ) Subjects receive 3 dos assign treatment ( GEN-003/M-2 , GEN-003 , placebo ) 3 week interval . Sampling mucocutaneous genital site viral shed do twice daily 28 day prior first immunization ( baseline shed ) , follow last immunization . Follow-up safety monitoring conduct 12 month last immunization .</brief_summary>
	<brief_title>Safety Immunogenicity Study Therapeutic HSV-2 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Men woman age 18 50 year , inclusive . Willing practice highly effective method contraception include use barrier method condom . Diagnosis genital HSV2 infection &gt; 1 year support ONE follow document medical history perform screening : Western blot HSV2 Typespecific polymerase chain reaction ( PCR ) viral culture Compatible clinical history AND HSV2 ELISA ( HerpSelect ) index value &gt; 3.5 A history least 3 9 report clinical occurrence prior 12 month , , currently suppressive therapy , history least 3 9 report clinical occurrence 12 month prior initiation suppressive therapy . Good general health status determine screen evaluation complete within 90 day prior immunization . Any range screen clinical laboratory value consider clinically significant Investigator . Patient provide write informed consent . Ability willingness perform comply study procedure include attend clinic visit schedule . Note : patient must provide , day randomization , minimum 28 ( equivalent 14 day ) baseline viral swab sample continue eligible randomize ) . On suppressive antiviral medication within 7 day baseline viral shed evaluation . Immunocompromised individual , include receive systemic corticosteroid immunosuppressive agent . Positive serologic test HIV1 infection ; positive hepatitis B surface antigen ( HBsAg ) antibody hepatitis C ( antiHCV ) . Active lesion consistent herpetic disease time schedule immunization . Pregnant nursing woman . Receipt investigational drug within 30 day first schedule day immunization . History hypersensitivity component vaccine . History genital HSV1 infection . History : ( 1 ) form ocular HSV infection , ( 2 ) HSVrelated erythema multiforme , ( 3 ) herpes meningitis encephalitis . Any condition opinion Investigator would interfere successful completion study protocol . History drug alcohol abuse , opinion Investigator , would interfere patient 's ability comply requirement study . Prior immunization vaccine contain HSV2 antigen . Receipt blood product within 90 day first immunization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HSV</keyword>
	<keyword>Herpes</keyword>
	<keyword>genital infection</keyword>
	<keyword>vaccine</keyword>
</DOC>